Sage Therapeutics, Inc. (NASDAQ:SAGE) Stock Holdings Lessened by Barclays PLC

Barclays PLC lessened its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 7.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 127,789 shares of the biopharmaceutical company’s stock after selling 10,829 shares during the quarter. Barclays PLC’s holdings in Sage Therapeutics were worth $923,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC raised its position in Sage Therapeutics by 245.3% during the second quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 2,782 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Sage Therapeutics by 66.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 4,672 shares in the last quarter. Creative Planning bought a new position in Sage Therapeutics during the third quarter valued at approximately $88,000. Quest Partners LLC raised its position in Sage Therapeutics by 14.5% during the second quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock valued at $128,000 after acquiring an additional 1,486 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in Sage Therapeutics during the third quarter valued at approximately $146,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Trading Down 2.0 %

Shares of Sage Therapeutics stock opened at $5.43 on Tuesday. The company’s fifty day simple moving average is $5.86 and its 200-day simple moving average is $7.91. The company has a market cap of $332.17 million, a price-to-earnings ratio of -0.97 and a beta of 0.87. Sage Therapeutics, Inc. has a 1 year low of $4.62 and a 1 year high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business had revenue of $11.87 million for the quarter, compared to analyst estimates of $10.80 million. During the same quarter in the prior year, the firm earned ($2.81) EPS. The firm’s quarterly revenue was up 337.1% on a year-over-year basis. As a group, research analysts forecast that Sage Therapeutics, Inc. will post -6.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SAGE. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Truist Financial cut their price objective on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, October 30th. Royal Bank of Canada raised shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research report on Thursday, November 21st. Wedbush dropped their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 9th. Finally, HC Wainwright reissued a “neutral” rating and issued a $14.00 price target on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Sage Therapeutics presently has an average rating of “Hold” and a consensus target price of $11.53.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.